Answers are grounded in this paper and cite their sources.
Introduction Palliative patients of head and neck cancer have very few treatment options with significant side effects. This study evaluated the safety and efficacy of low dose Nivolumab in palliative head and neck cancer cases. Methodology The study was a retrospective study of 71 palliative patients of head and neck cancer (palliative either after initial chemotherapy, radiotherapy or chemoradiotherapy and upfront palliative cases) from Feb 2022 to Feb 2025. Patients' data were extracted who were treated with low dose Nivolumab 20 mg 3 weekly with or without oral metronomic agents. Gefitinib 250 mg daily and Methotrexate 10 mg once weekly was given with Nivolumab 20 mg IV 3 weekly regimen. ORR after three and six cycles of Nivolumab were assessed. Adverse effects were recorded as per CTCAE version 5.0. Overall survival and progression free survival with respect to response rate were assessed and presented in percentages and graphs. Results Most common cases were of oral cavity cancer (43.66%) followed by larynx (30.99%), oropharynx (16.90%) and hypopharynx (8.45%). The ORR is 53.51% in our study with CR of 15.49%, and PR of 38.02%0.16 patients (22.53%) had SD while 17 (23.94%) patients had PD. One-year overall survival for patients with CR was 81.8%, PR was 33.3%. One-year PFS for patients with CR is 27.3% and PR is 3.7% while it is nil in patients having SD and PD). Most common side effects in our study were fatigue (59.15%) and gastritis (57.74%). Conclusion The early results with low dose Nivolumab are reasonable in terms of response rate and manageable side effects. The observed responses reflect the combined effect of low dose nivolumab with or without prior therapies, and that the independent contribution of nivolumab cannot be determined from this study design.
No takes yet. Share an insight, caveat, or question.
Baral et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: